Everolimus Alternatives Compared
Everolimus | Ibrance | Kisqali |
|
---|
Everolimus | Ibrance (palbociclib) | Kisqali (ribociclib) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Neuroendocrine Carcinoma, Breast Cancer, Organ Transplant - Rejection Prophylaxis, Brain Tumor, Renal Angiomyolipoma, Pancreatic Cancer, Renal Cell Carcinoma, Subependymal Giant Cell... View more |
Prescription only
Ibrance is a CDK4/6 inhibitor that may be used to treat advanced or metastatic hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer in combination... View more |
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer. Kisqali may also be used for purposes not listed in this medication guide. |
Related suggestions Breast Cancer
Popular comparisons
|
|||||||||||||||
More about Everolimus | More about Ibrance (palbociclib) | More about Kisqali (ribociclib) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Everolimus has an average rating of 5.6 out of 10 from a total of 29 ratings on Drugs.com. 46% of reviewers reported a positive effect, while 38% reported a negative effect. |
Ibrance has an average rating of 6.7 out of 10 from a total of 82 ratings on Drugs.com. 62% of reviewers reported a positive effect, while 30% reported a negative effect. |
Kisqali has an average rating of 8.5 out of 10 from a total of 25 ratings on Drugs.com. 83% of reviewers reported a positive effect, while 4% reported a negative effect. |
||||||||||||||||
Drug Class | ||||||||||||||||||
Side Effects | ||||||||||||||||||
See also: everolimus side effects in more detail. |
See also: Ibrance side effects in more detail. |
See also: Kisqali side effects in more detail. |
||||||||||||||||
Generic Availability | ||||||||||||||||||
Lower cost generic |
||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all everolimus prices |
View all Ibrance prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||||||||||
Dosage Forms Available | ||||||||||||||||||
|
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
Afinitor, Afinitor Disperz, Zortress |
N/A |
N/A |
||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
35 hours |
29 hours |
54.7 hours |
||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 516 drugs are known to interact with everolimus:
|
A total of 457 drugs are known to interact with Ibrance:
|
A total of 709 drugs are known to interact with Kisqali:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
March 30, 2009 |
February 03, 2015 |
March 13, 2017 |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.